Phytate Prevents Porosis

ironjustice

2019-01-01 07:14:57 UTC

Post by ironjustice
This would be my freeeee bisphosphonate .. a .. gain .. http://tinyurl.com/2wuhuk
Protective effect of myo-inositol hexaphosphate (phytate) on bone mass
loss in postmenopausal women
Ángel A. López-González, Félix Grases, Nieves Monroy, Bartolome Marí,
Mª Teófila Vicente-Herrero, Fernando Tur and Joan Perelló
European Journal of Nutrition , 2012
Introduction
Abstract
The objective of this paper was to evaluate the relationship between
urinary concentrations of InsP6, bone mass loss and risk fracture in
postmenopausal women.
Materials and methods
A total of 157 postmenopausal women were included in the study: 70 had
low (≤0.76 μM), 42 intermediate (0.76–1.42 μM) and 45 high (≥1.42 μM)
urinary phytate concentrations. Densitometry values for neck were
measured at enrollment and after 12 months (lumbar spine and femoral
neck), and 10-year risk fracture was calculated using the tool FRAX®.
Results
Individuals with low InsP6 levels had significantly greater bone mass
loss in the lumbar spine (3.08 ± 0.65 % vs. 0.43 ± 0.55 %) than did
those with high phytate levels. Moreover, a significantly greater
percentage of women with low than with high InsP6 levels showed more
than 2 % of bone mass loss in the lumbar spine (55.6 vs. 20.7 %). The
10-year fracture probability was also significantly higher in the low-
phytate group compared to the high-phytate group, both in hip (0.37 ±
0.06 % vs 0.18 ± 0.04 %) and major osteoporotic fracture (2.45 ± 0.24
% vs 1.83 ± 0.11 %).
Discussion
It can be concluded that high urinary phytate concentrations are
correlated with reduced bone mass loss in lumbar spine over 12 months
and with reduced 10-year probability of hip and major osteoporotic
fracture, indicating that increased phytate consumption can prevent
development of osteoporosis.
----------------
You know there seems to be a bisphosphonate found in your food.
Phytate / phytic acid , found in the chaff of your grain and in your
plants is compared to Etidronate a prescribed bisphosphonate , a
crystalization inhibitor , used for osteoporosis.
http://tinyurl.com/2wuhuk
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk

Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis.
Grases F, Perello J, Isern B, Prieto RM.
Laboratory of Renal Lithiasis Research and Biomineralization,
University Institute of Health Sciences Research (IUNICS),
University of Balearic Islands, 07122 Palma de Mallorca, Spain. ***@uib.es

BACKGROUND:
Calcinosis cutis is a disorder caused by abnormal deposits of calcium phosphate in the skin and is observed in diverse disorders. Myo-inositol hexaphosphate (InsP(6)) is a diet-dependent molecule found in all mammalian fluids and tissues, which exhibits an extraordinary capacity as a crystallization inhibitor of calcium salts.
OBJECTIVES:
To establish the effects of topically administered InsP(6) cream on artificially provoked dystrophic calcifications in soft tissues.
METHODS: Fourteen male Wistar rats were randomly assigned into two groups: control and treated groups. Rats were fed with an InsP(6)-free or phytate diet. Plaque formation was induced by subcutaneous injection of 0.1% KMnO(4)solution. From 4 days before plaque induction to the end of the experiment, control rats were treated topically with a standard cream, whereas treated rats were treated with the same cream with 2% InsP(6) or phytate (as sodium salt). Calcification of plaques was allowed to proceed for 10 days. InsP(6) in urine was determined. The plaques were excised and weighed. RESULTS: It was found that when InsP(6) was administered topically through a moisturizing cream (2% InsP(6)-rich), the plaque size and weight were notably and significantly reduced compared with the control group (1.6 +/- 1.1 mg InsP(6)-treated, 26.7 +/- 3.0 mg control). The InsP(6) urinary levels for animals treated with the InsP(6)- enriched cream were considerably and significantly higher than those found in animals treated topically with the cream without InsP(6) (16.96 +/- 4.32 mg L(-1) InsP(6)-treated, 0.06 +/- 0.03 mg L(-1) control).
CONCLUSIONS:
This demonstrates the important capacity of InsP(6) as a crystallization inhibitor and also demonstrates that it is possible to propose topical use as a new InsP(6) administration route.

PMID: 15888163